On the public citation graph

Comparative Effectiveness of Entecavir Versus Tenofovir for Preventing Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: A Systematic Review and Meta‐Analysis

0 signed · 109 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

1 of the 26 references listed on this page is in the Retraction Watch database as retracted (export 2026-11-18): 10.1001/jamaoncol.2018.4070 (notice 2019-04-25).

Dataset join, best-effort; this page does not check the publisher record. Retraction Watch data via Crossref Labs, used with credit; OpenCitations Index (CC0) and Meta (CC BY 4.0); dataset doi:10.7910/DVN/WT8VOA (CC BY 4.0).

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/jama.295.1.65openalex-snapshot
Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level
inferredcites →https://doi.org/10.1001/jamaoncol.2018.4070openalex-snapshot
Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B
inferredcites →https://doi.org/10.1002/hep.28156openalex-snapshot
AASLD guidelines for treatment of chronic hepatitis B
inferredcites →https://doi.org/10.1002/hep.28280openalex-snapshot
Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta‐analysis
inferredcites →https://doi.org/10.1002/sim.1186openalex-snapshot
Quantifying heterogeneity in a meta‐analysis
inferredcites →https://doi.org/10.1007/s10620-017-4448-7openalex-snapshot
Effectiveness and Safety of Entecavir or Tenofovir in a Spanish Cohort of Chronic Hepatitis B Patients: Validation of the Page-B Score to Predict Hepatocellular Carcinoma
inferredcites →https://doi.org/10.1016/j.clinre.2017.06.008openalex-snapshot
A long-term multicenter study: Entecavir versus Tenofovir in treatment of nucleos(t)ide analogue-naive chronic hepatitis B patients
inferredcites →https://doi.org/10.1016/j.cmi.2017.02.001openalex-snapshot
Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective cohort study
inferredcites →https://doi.org/10.1016/j.ijid.2014.09.004openalex-snapshot
Comparable efficacy of tenofovir versus entecavir and predictors of response in treatment-naïve patients with chronic hepatitis B: a multicenter real-life study
inferredcites →https://doi.org/10.1016/j.jhep.2010.02.035openalex-snapshot
Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: A systematic review
inferredcites →https://doi.org/10.1016/j.jhep.2017.03.021openalex-snapshot
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
inferredcites →https://doi.org/10.1016/j.jhep.2019.03.028openalex-snapshot
A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea
inferredcites →https://doi.org/10.1016/s0618-8278(19)30259-2openalex-snapshot
LBP-13-Effect of treatment of hepatitis B patients with tenofovir disoproxil or entecavir on risk of hepatocellular cancer death in a U.S. Cohort
inferredcites →https://doi.org/10.1053/j.gastro.2011.12.061openalex-snapshot
Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma
inferredcites →https://doi.org/10.1053/j.gastro.2019.09.025openalex-snapshot
Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China
inferredcites →https://doi.org/10.1056/nejmoa013215openalex-snapshot
Hepatitis B e Antigen and the Risk of Hepatocellular Carcinoma
inferredcites →https://doi.org/10.1097/md.0000000000013983openalex-snapshot
Comparison of the long-term efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naïve HBeAg-positive patients with chronic hepatitis B
inferredcites →https://doi.org/10.1111/apt.12344openalex-snapshot
Meta‐analysis: the impact of oral anti‐viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B
inferredcites →https://doi.org/10.1111/hepr.13194openalex-snapshot
Remaining hepatocellular carcinoma risk in chronic hepatitis B patients receiving entecavir/tenofovir in South Korea
inferredcites →https://doi.org/10.1111/jvh.12971openalex-snapshot
Mortality, liver transplantation and hepatic complications in patients with treatment‐naïve chronic hepatitis B treated with entecavir vs tenofovir
inferredcites →https://doi.org/10.1111/liv.13682openalex-snapshot
Liver diseases: A major, neglected global public health problem requiring urgent actions and large‐scale screening
inferredcites →https://doi.org/10.1136/bmj.327.7414.557openalex-snapshot
Measuring inconsistency in meta-analyses
inferredcites →https://doi.org/10.1136/gutjnl-2019-318947openalex-snapshot
Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis
inferredcites →https://doi.org/10.14309/ajg.0000000000000428openalex-snapshot
Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B
inferredcites →https://doi.org/10.4103/sjg.sjg_49_18openalex-snapshot
Real-world single-center experience with entecavir and tenofovir disoproxil fumarate in treatment-naïve and experienced patients with chronic hepatitis B
inferredcites →https://doi.org/10.7326/0003-4819-144-6-200603210-00010openalex-snapshot
Evaluation of the Quality of Prognosis Studies in Systematic Reviews

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4775921openalex-extracted
Chronic Hepatitis B Patients Under Nucleos(t)ide Analogues Treatment with Omicron BA.5 Infection: A Retrospective Study in South China
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2022.19407openalex-snapshot
Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir Treatment for Chronic Hepatitis B Virus
inferred← citeshttps://doi.org/10.1002/14651858.cd015642openalex-snapshot
Tenofovir versus entecavir for children and adults with chronic hepatitis B
inferred← citeshttps://doi.org/10.1002/aid2.13362openalex-snapshot
Entecavir versus tenofovir disoproxil fumarate on the reduction of incidence of hepatocellular carcinoma in patients with chronic hepatitis B‐related liver cirrhosis
inferred← citeshttps://doi.org/10.1002/aid2.13391openalex-snapshot
Efficacy of entecavir versus tenofovir disoproxil fumarate in preventing hepatocellular carcinoma—The jury is out
inferred← citeshttps://doi.org/10.1002/hep.31438openalex-snapshot
REPLY:
inferred← citeshttps://doi.org/10.1002/hep.32155openalex-snapshot
Letter to the Editor: Is HBV genotype strongly associated with HCC risk in patients with chronic hepatitis B?
inferred← citeshttps://doi.org/10.1007/978-3-031-20521-7_3openalex-snapshot
New Drugs in Synthesis Research for Viral Diseases
inferred← citeshttps://doi.org/10.1007/s00432-025-06082-4openalex-snapshot
Comparison of tenofovir versus entecavir for preventing hepatocellular carcinoma in chronic hepatitis B patients: an umbrella review and meta-analysis
inferred← citeshttps://doi.org/10.1007/s00535-020-01726-3openalex-snapshot
Secondary prevention for hepatocellular carcinoma in patients with chronic hepatitis B: are all the nucleos(t)ide analogues the same?
inferred← citeshttps://doi.org/10.1007/s00535-020-01750-3openalex-snapshot
Tenofovir–disoproxil–fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infection
inferred← citeshttps://doi.org/10.1007/s11901-022-00588-yopenalex-snapshot
Risk of HCC in Patients with HBV, Role of Antiviral Treatment
inferred← citeshttps://doi.org/10.1007/s12072-022-10310-1openalex-snapshot
Cost-effectiveness of antiviral therapy in untreated compensated cirrhosis patient with serum HBV–DNA level < 2000 IU/mL
inferred← citeshttps://doi.org/10.1007/s12072-022-10357-0openalex-snapshot
Comparable outcomes of decompensated chronic hepatitis B patients treated with entecavir or tenofovir: an 8-year cohort study
inferred← citeshttps://doi.org/10.1007/s12072-022-10411-xopenalex-snapshot
Effectiveness of entecavir vs tenofovir disoproxil fumarate for functional cure of chronic hepatitis B in an international cohort
inferred← citeshttps://doi.org/10.1016/j.asjsur.2023.09.057openalex-snapshot
Enhanced prognosis of HCC patients undergoing radical treatments with tenofovir versus entecavir: A meta-analysis based on propensity score matching studies
inferred← citeshttps://doi.org/10.1016/j.bioorg.2024.107539openalex-snapshot
Gypenoside L inhibits hepatocellular carcinoma by targeting the SREBP2-HMGCS1 axis and enhancing immune response
inferred← citeshttps://doi.org/10.1016/j.cgh.2021.03.014openalex-snapshot
Effects of Tenofovir vs Entecavir on Risk of Hepatocellular Carcinoma in Patients With CHB: A Comment for Moving Forward
inferred← citeshttps://doi.org/10.1016/j.cld.2021.06.006openalex-snapshot
Controversies in the Management of Hepatitis B
inferred← citeshttps://doi.org/10.1016/j.cld.2023.05.005openalex-snapshot
Are the New Nucleos(t)ide Analogs Better than the Old Nucleos(t)ide Analogs?
inferred← citeshttps://doi.org/10.1016/j.dld.2022.04.004openalex-snapshot
Nucleo(s)tide analogue withdrawal in chronic hepatitis B virus infection: Beyond the HBsAg loss
inferred← citeshttps://doi.org/10.1016/j.gendis.2026.102483openalex-snapshot
2-Phenylnaphthalene derivatives as RRM2 inhibitors with dual anti-tumor and anti-HBV activity in hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1016/j.jhep.2021.09.017openalex-snapshot
Methodological challenges of performing meta-analyses to compare the risk of hepatocellular carcinoma between chronic hepatitis B treatments
inferred← citeshttps://doi.org/10.1016/j.jhep.2022.12.007openalex-snapshot
Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: Individual patient data meta-analysis
inferred← citeshttps://doi.org/10.1016/j.jhep.2026.04.024openalex-snapshot
Systemic therapy for HCC: Doublets, triplets and beyond
inferred← citeshttps://doi.org/10.1016/j.jhepr.2024.101128openalex-snapshot
HBV-related HCC development in mice is STAT3 dependent and indicates an oncogenic effect of HBx
inferred← citeshttps://doi.org/10.1016/j.livres.2024.11.003openalex-snapshot
Patients with chronic hepatitis B under nucleos(t)ide analog therapy with Omicron BA.5 infection: A retrospective study in South China
inferred← citeshttps://doi.org/10.1016/j.saa.2024.124792openalex-snapshot
Multi-spectral and docking assessments to explore the combination of an antiviral drug, entecavir with bovine serum albumin
inferred← citeshttps://doi.org/10.1016/s0140-6736(22)01200-4openalex-snapshot
Hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1016/s2468-1253(20)30249-1openalex-snapshot
Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1016/s2468-1253(22)00041-3openalex-snapshot
Hepatocellular carcinoma: measures to improve the outlook in sub-Saharan Africa
inferred← citeshttps://doi.org/10.1038/s41598-020-70433-zopenalex-snapshot
Hepatocellular carcinoma and death and transplantation in chronic hepatitis B treated with entecavir or tenofovir disoproxil fumarate
inferred← citeshttps://doi.org/10.1038/s41598-024-58807-zopenalex-snapshot
TDF and TAF inhibit liver cancer cell migration, invasion via p7TP3
inferred← citeshttps://doi.org/10.1055/a-1498-2512openalex-snapshot
S3-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion – (AWMF-Register-Nr. 021-11)
inferred← citeshttps://doi.org/10.1080/14740338.2022.2045271openalex-snapshot
Safety of current antiviral drugs for chronic hepatitis B
inferred← citeshttps://doi.org/10.1080/17474124.2023.2212161openalex-snapshot
Tenofovir versus entecavir on the prognosis of hepatitis B virus-related hepatocellular carcinoma: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1093/gastro/goag060openalex-snapshot
Current advances and future directions in the management of HBV-related hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1097/lvt.0000000000000227openalex-snapshot
Entecavir versus tenofovir on the recurrence of hepatitis B–related HCC after liver transplantation: A multicenter observational study
inferred← citeshttps://doi.org/10.1111/apt.16692openalex-snapshot
Editorial: the three tenors in HBV—TDF, TAF and now TMF. Authors' reply
inferred← citeshttps://doi.org/10.1111/apt.17438openalex-snapshot
Entecavir versus tenofovir on prognosis of hepatitis B virus‐related hepatocellular carcinoma after curative hepatectomy
inferred← citeshttps://doi.org/10.1111/apt.17506openalex-snapshot
Review article: Available modalities for screening and imaging diagnosis of hepatocellular carcinoma—Current gaps and challenges
inferred← citeshttps://doi.org/10.1111/apt.17712openalex-snapshot
Letter: Association between aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B
inferred← citeshttps://doi.org/10.1111/jgh.15249openalex-snapshot
HCC risk reduction with oral nucleos(t)ide analogues in patients with chronic hepatitis B: Not perfect, not good enough
inferred← citeshttps://doi.org/10.1111/jgh.15783openalex-snapshot
Lower risk of hepatocellular carcinoma with tenofovir than entecavir treatment in subsets of chronic hepatitis B patients: an updated meta‐analysis
inferred← citeshttps://doi.org/10.1111/jvh.13572openalex-snapshot
Efficacy of entecavir versus tenofovir in preventing hepatocellular carcinoma in patients with chronic hepatitis B with maintained virologic response
inferred← citeshttps://doi.org/10.1155/2020/8871024openalex-snapshot
Risk of Hepatocellular Carcinoma Remains High in Patients with HBV-Related Decompensated Cirrhosis and Long-Term Antiviral Therapy
inferred← citeshttps://doi.org/10.1155/2022/9567041openalex-snapshot
Microvascular Invasion in Hepatocellular Carcinoma: A Review of Its Definition, Clinical Significance, and Comprehensive Management
inferred← citeshttps://doi.org/10.1159/000512780openalex-snapshot
Comparison of Tenofovir and Entecavir in the Prevention of Hepatocellular Carcinoma Occurrence in Patients with Chronic Hepatitis B
inferred← citeshttps://doi.org/10.1186/s12873-025-01285-xopenalex-snapshot
The impact of virtual reality (VR) on pain management in the emergency department: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1186/s12885-022-09413-7openalex-snapshot
Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis
inferred← citeshttps://doi.org/10.1186/s12964-023-01357-0openalex-snapshot
Non-coding RNA methylation modifications in hepatocellular carcinoma: interactions and potential implications
inferred← citeshttps://doi.org/10.1186/s12967-024-05027-8openalex-snapshot
Role of Hippo pathway dysregulation from gastrointestinal premalignant lesions to cancer
inferred← citeshttps://doi.org/10.12677/jcpm.2024.31008openalex-snapshot
Advances in the Treatment of Microvascular Invasion in Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.14309/ajg.0000000000001157openalex-snapshot
Outcomes of Sequential Therapy With Tenofovir Alafenamide After Long-term Entecavir
inferred← citeshttps://doi.org/10.14309/ajg.0000000000002234openalex-snapshot
Personalized Antiviral Drug Selection in Patients With Chronic Hepatitis B Using a Machine Learning Model: A Multinational Study
inferred← citeshttps://doi.org/10.17998/jlc.2022.11.07openalex-snapshot
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
inferred← citeshttps://doi.org/10.18632/aging.202573openalex-snapshot
No difference in hepatocellular carcinoma risk in chronic hepatitis B patients treated with tenofovir vs entecavir: evidence from an updated meta-analysis
inferred← citeshttps://doi.org/10.20517/2394-5079.2020.138openalex-snapshot
Optimize nucleot(s)ide analogues’ to prevent hepatocellular carcinoma in patients with chronic hepatitis B: a lesson from real-world evidence
inferred← citeshttps://doi.org/10.20517/2394-5079.2021.113openalex-snapshot
Use of tenofovir disoproxil fumarate is associated with a lower risk of hepatocellular carcinoma than entecavir in patients with chronic hepatitis B
inferred← citeshttps://doi.org/10.20517/2394-5079.2021.144openalex-snapshot
Overview of methodologies and statistical strategies in observational studies and meta-analyses on the risk of hepatocellular carcinoma in patients with chronic hepatitis B on entecavir or tenofovir therapy
inferred← citeshttps://doi.org/10.20964/2022.12.76openalex-snapshot
Analytical Detection of Hepatitis B Antiviral Drug Entecavir using Hemoglobin Modified Nitrogen-Doped Carbon Nanotube Sensor
inferred← citeshttps://doi.org/10.21037/hbsn-23-528openalex-snapshot
The power of prevention: how tenofovir and entecavir are changing the game in hepatocellular carcinoma
inferred← citeshttps://doi.org/10.21203/rs.3.rs-2568480/v1openalex-snapshot
Entecavir versus tenofovir on recurrence of hepatitis B virus–related hepatocellular carcinoma in liver transplantation
inferred← citeshttps://doi.org/10.21203/rs.3.rs-3024671/v1openalex-snapshot
TDF and TAF inhibit hepatocellular carcinoma cell migration, invasion via p7TP3
inferred← citeshttps://doi.org/10.3348/kjr.2022.0822openalex-snapshot
2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.3350/cmh.2021.0179openalex-snapshot
Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma
inferred← citeshttps://doi.org/10.3350/cmh.2022.0294openalex-snapshot
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
inferred← citeshttps://doi.org/10.3350/cmh.2022.0342openalex-snapshot
Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virus infection
inferred← citeshttps://doi.org/10.3350/cmh.2024.0055openalex-snapshot
Extrahepatic malignancies and antiviral drugs for chronic hepatitis B: A nationwide cohort study
inferred← citeshttps://doi.org/10.3389/fmed.2021.637126openalex-snapshot
Tenofovir Disoproxil Fumarate Is Superior to Entecavir in Reducing Hepatitis B Surface Antigen for Chronic Hepatitis B in China: 2-Year Comprehensive Comparative Result of a Matched Comparative Study
inferred← citeshttps://doi.org/10.3389/fonc.2023.1174788openalex-snapshot
A novel nomogram based on GD for predicting prognosis in hepatocellular carcinoma
inferred← citeshttps://doi.org/10.3390/cancers14112617openalex-snapshot
Systematic Review with Meta-Analysis: Comparison of the Risk of Hepatocellular Carcinoma in Antiviral-Naive Chronic Hepatitis B Patients Treated with Entecavir versus Tenofovir: The Devil in the Detail
inferred← citeshttps://doi.org/10.3390/cancers15112936openalex-snapshot
Inverse Propensity Score-Weighted Analysis of Entecavir and Tenofovir Disoproxil Fumarate in Patients with Chronic Hepatitis B: A Large-Scale Multicenter Study
inferred← citeshttps://doi.org/10.3390/cancers15205046openalex-snapshot
Unveiling the Role of Tumor-Infiltrating T Cells and Immunotherapy in Hepatocellular Carcinoma: A Comprehensive Review
inferred← citeshttps://doi.org/10.3390/cancers16030550openalex-snapshot
Triptolide Reduces Neoplastic Progression in Hepatocellular Carcinoma by Downregulating the Lipid Lipase Signaling Pathway
inferred← citeshttps://doi.org/10.3390/cells10113091openalex-snapshot
Treatment for Viral Hepatitis as Secondary Prevention for Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.3390/jcm10020353openalex-snapshot
Stratification of Hepatocellular Carcinoma Risk Following HCV Eradication or HBV Control
inferred← citeshttps://doi.org/10.3390/jcm11041126openalex-snapshot
Hepatocellular Carcinoma in Hepatitis B Virus-Infected Patients and the Role of Hepatitis B Surface Antigen (HBsAg)
inferred← citeshttps://doi.org/10.3390/jcm13226770openalex-snapshot
Beyond the Liver: A Comprehensive Review of Strategies to Prevent Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.3390/jpm13060964openalex-snapshot
Current Therapy of Chronic Viral Hepatitis B, C and D
inferred← citeshttps://doi.org/10.4251/wjgo.v17.i11.112689openalex-snapshot
Effect of antiviral therapy on 3-year recurrence and prognosis of hepatocellular carcinoma after curative radiofrequency ablation
inferred← citeshttps://doi.org/10.53469/jcmp.2025.07(02).20openalex-snapshot
Progress in Liver Cancer Associated to Autoimmune Liver Disease
inferred← citeshttps://doi.org/10.61841/rgnxfv10openalex-snapshot
COMPARATIVE EFFECTIVENESS OF ENTECAVIR VERSUS TENOFOVIR FOR PREVENTING HEPATOCELLULAR CARCINOMA IN PATIENTS WITH CHRONIC HEPATITIS B: A COMPREHENSIVE SYSTEMATIC REVIEW
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.